Silexion Therapeutics Corp (NASDAQ:SLXN) Sees Large Decline in Short Interest

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 16,557 shares, a decrease of 89.3% from the May 31st total of 154,973 shares. Currently, 4.1% of the shares of the company are sold short. Based on an average trading volume of 233,740 shares, the days-to-cover ratio is currently 0.1 days.

Silexion Therapeutics Stock Up 0.7%

SLXN stock opened at $2.75 on Friday. Silexion Therapeutics has a fifty-two week low of $2.31 and a fifty-two week high of $223.60. The firm’s 50-day simple moving average is $5.20 and its 200 day simple moving average is $13.74. The stock has a market cap of $1.16 million, a PE ratio of -0.03 and a beta of -0.32.

Silexion Therapeutics (NASDAQ:SLXN) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($12.90) by $12.05. Equities analysts forecast that Silexion Therapeutics will post -45.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Monday, June 15th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Silexion Therapeutics presently has an average rating of “Hold”.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.